NCT03457532
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MET
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years to 70 Years (Adult), Senior)
Location of Metastases:
Additional Notes: Patients must have c-MET alteration (amplification, over-expression or c-MET axon 14 skipping)
Exclusions:
https://ClinicalTrials.gov/show/NCT03457532